Les expressions comme achat cialis en ligne fiable montrent l’importance accordée à la confiance dans le processus. La fiabilité se mesure par l’existence d’une autorisation officielle délivrée par les autorités sanitaires nationales. Seules les pharmacies vérifiées affichent les logos réglementaires. L’absence de certification expose le consommateur à des médicaments inefficaces ou mal dosés, pouvant entraîner une aggravation des troubles cardiovasculaires.
Generisches Combivir gehört in die Medikamenten Gruppe der sogenannten Transcriptase-Hemmer und behandelt in Kombination mit anderen Medikamenten HIV-Infektionen. Mehr Information »
Generisches Retrovir wirkt in Kombination mit anderen Medikamenten bei HIV-Infektionen. Schwangeren HIV-positiven Frauen hilft es, den Virus nicht an den Fötus weiterzugeben. Mehr Information »
Danke für die Nachfrage,
Ich habe die Pillen erhalten und hatte die Möglichkeit sie zu probieren. Ich bin sehr
glücklich, wie auch meine Freundin.
Danke
- DN
Landmark Phase III studies for dolutegravir and lamivudine - The Pharma Letter
The Pharma LetterLandmark Phase III studies for dolutegravir and lamivudineThe Pharma LetterViiV Healthcare, the specialty HIV/AIDS company majority owned by GlaxoSmithKline (LSE: GSK), today announced positive headline results from its Phase III GEMINI study program.
China Biopharma Company Risks De-Listing After Data Fraud - BioSpace (press release) (blog)
BioSpace (press release) (blog)China Biopharma Company Risks De-Listing After Data FraudBioSpace (press release) (blog)The report stated that the WHO Prequalification Team (PQT) inspected the company's Chennai, India facility between October 13 and 17, 2014, focusing on Study No.
Antiretroviral Contraindications and Drug Interactions - Infectious Disease Advisor
Antiretroviral Contraindications and Drug InteractionsInfectious Disease AdvisorSevere renal impairment or ESRD (CrCl .
ViiV has 'another formidable asset' in rivalry with Gilead - The Pharma Letter
The Pharma LetterViiV has 'another formidable asset' in rivalry with GileadThe Pharma LetterClaims by ViiV Healthcare's chief executive Deborah Waterhouse (pictured above) that her company is doing more than just playing second fiddle to US biotech Gilead Science (Nasdaq: GILD) in the HIV space have been backed up by an analyst at .
